lilly retatrutide Eli Preparing Applications After Positive Weight-Loss Data Eli Lilly’s Phase 3 data

Should GLP-1 patches complete clinical development and receive regulatory approval in future, they would undergo health technology assessment by NICE to determine cost-effectiveness and appropriate positioning within NHS treatment pathways

These drugs mimic the glucagon-like peptide-1 hormone, which regulates appetite and insulin secretion

Jan 20, 2026 9 min read IN THIS ARTICLE KEY TAKEAWAYS GLP-1 medications can reduce appetite and temporarily lower energy

This novel treatment, nearing Phase 1 clinical trials, could help prevent weight regain post-GLP-1 analogue use by mimicking the incretin hormone to suppress appetite and regulate blood sugar, thus aiding in the management of obesity and diabetes